Relative Benefits, Risks of AAV Induction and Maintenance Therapies Reviewed

Relative Benefits, Risks of AAV Induction and Maintenance Therapies Reviewed

288558

Relative Benefits, Risks of AAV Induction and Maintenance Therapies Reviewed

The antibody rituximab is a good alternative to cyclophosphamide for inducing remission in people with ANCA-associated vasculitis (AAV), and is better than azathioprine as a maintenance therapy, researchers reported. These were among the findings from a recent review study that investigated the relative benefits and risks associated with different treatment regimes for AAV patients. The study, “Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments,” was…

You must be logged in to read/download the full post.